Of the 44 subjects with positive ONCOblot® Tissue of Origin Cancer Tests, i.e., with evidence for an ENOX2 transcript variant, non-small cell lung (20%), breast (16%), colorectal (9%), blood cell, ovarian, prostate and cervical all at 7% each were among the most prevalent based on molecular weight and isoelectric point characteristics compared to data base values from patients with clinically diagnosed cancers (Table 1). This evidence concerns the gene ENOX2 and cancer.